1. Comparison of the new American Joint Committee on Cancer substratification in node-negative pT2 urothelial carcinoma of the bladder: analysis of patient outcomes in a contemporary series.
- Author
-
Gakis G, Schilling D, Renninger M, Seibold J, Sievert KD, and Stenzl A
- Subjects
- Adult, Aged, Aged, 80 and over, Biopsy, Needle, Epidemiologic Methods, Female, Humans, Lymphatic Metastasis, Male, Middle Aged, Neoplasm Invasiveness, Neoplasm Recurrence, Local, Neoplasm Staging, Prognosis, Treatment Outcome, United States, Urinary Bladder Neoplasms mortality, Urinary Bladder Neoplasms surgery, Cystectomy methods, Lymph Node Excision, Lymph Nodes pathology, Urinary Bladder Neoplasms pathology
- Abstract
Objective: • To determine whether there is a difference in survival in patients with node-negative pT2a vs pT2b urothelial carcinoma of the bladder (UBC), as recent studies suggest that the new American Joint Committee on Cancer substratification may not have prognostic significance., Patients and Methods: • Of 252 patients undergoing radical cystectomy (RC) and extended bilateral pelvic lymphadenectomy (ePLND) between 1999 and 2009, 72 (28.6%), with a mean (range) age of 66 (44-83) years (50 men, 22 women), had pathologically confirmed pT2 UCB. • Fisher's exact test and Cox regression analysis were used for uni- and multivariate analysis of risk factors of recurrence at a median (range) follow-up of 28 (2.2-115.7) months. • Kaplan-Meier plots were used to estimate the impact of pT2 substratification in lymph node (LN)-negative disease on recurrence-free (RFS) and cancer-specific (CSS) survival using log-rank test., Results: • Of the 72 patients, 39 had pT2a (54.2%) and 33 pT2b UCB (45.8%) on definitive histological examination. The median (range) number of LNs removed was 19 (6-38) in pT2a and 22 (4-36) in pT2b (P = 0.31) UCB. • At RC, there was LN-positive disease in one patient with pT2a UCB, whereas seven patients with pT2b UCB had LN-positive disease (P = 0.02). • The median (range) number of LNs removed in LN-positive disease was 18 (11-30) and in LN-negative disease was 20 (4-38) (P = 0.52). • In LN-negative disease, actuarial 5-year RFS was 85.9% in patients with pT2a UCB vs 37.5% in those with pT2b UCB (P < 0.001). Actuarial 5-year CSS was 84.8% in patients with LN-negative pT2a UCB vs 59.6% in patients with LN-negative pT2b UCB (P = 0.01). • In Cox regression analysis, pT2 substratification was the only independent risk factor of recurrence and cancer-specific death (P < 0.001 and P = 0.008)., Conclusions: • In this contemporary series of patients undergoing RC with ePLND, there was a significant difference in RFS and CSS between LN-negative pT2a and pT2b UCB, and pT2 substratification was the only risk factor of recurrence and cancer-specific death. • These data are supportive of the current concept of substratification in LN-negative pT2 UCB., (© 2010 THE AUTHORS. JOURNAL COMPILATION © 2010 BJU INTERNATIONAL.)
- Published
- 2011
- Full Text
- View/download PDF